


correvio



Third Quarter 2019 Financial Results Conference Call

November 14, 2019



NASDAQ: CORV / TSX: CORV

- Certain statements in this presentation contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” under applicable Canadian securities legislation (collectively, “forward-looking statements”). Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenue or performance, capital expenditures, financing needs and other information that may not be based on historical fact. Forward-looking statements can often be identified by the use of terminology such as “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us based on our experience and perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate.
- By their very nature, forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These forward-looking statements include, but are not limited to: statements relating to the Company’s plans to submit a regulatory filing for Trevynt in Europe in the second half of 2020; and statements relating to the approval of Brinavess by the FDA and the timing of any such approval. In particular, no statement herein should be understood to mean that: (i) that our resubmission will be deemed to be complete by the FDA; (ii) that the FDA will find our underlying clinical trial data to be acceptable; (iii) that the FDA will find our manufacturing sites acceptable and validate them; or (iv) that our NDA will ultimately be approved by the FDA. Furthermore, the timing of any action by the FDA and possible regulatory paths forward cannot be guaranteed, in that, for example: (i) the FDA plans to hold an Advisory Committee meeting; (ii) the FDA may miss its own required deadlines (including for example, the PDFUA date); and (iii) the FDA may require further information or additional clinical studies. Finally, no statement provided herein should be understood to provide an estimate of the current or future prevalence of atrial fibrillation or the market potential for Brinavess in the United States.
- By their very nature, forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. A detailed discussion of the risks and uncertainties facing Correvio Pharma Corp. (“Correvio”) are discussed in the annual reports and detailed from time to time in our other filings with the Securities and Exchange Commission (“SEC”) available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. In particular, we direct your attention to Correvio’s Annual Report on Form 40-F for the year ended December 31, 2018 and to its quarterly report filed August 14, 2019 for the second quarter of 2019. All of the risks and uncertainties disclosed in these filings are hereby incorporated by reference in their entirety.
- While Correvio makes these forward-looking statements in good faith, given these risks, uncertainties and factors, you are cautioned not to place undue reliance on any forward-looking statements made in this presentation. All forward-looking statements made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements to reflect subsequent events or circumstances, except as required by law. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to their inherent uncertainty.



- Following Type C meeting with FDA Correvio resubmitted Brinavess NDA in Q2 2019
- Resubmission accepted by FDA in July 2019
- FDA Advisory Committee scheduled for Dec 10, 2019
- PDUFA target action date of December 24, 2019
- Eligible to apply for formal patent extensions into 2031
- Exploring strategic transaction opportunities



SPECTRUM

- Post authorization safety study (EU)
- 1,778 unique patients with 2,009 treatment episodes at 53 centers in 6 countries
- 70.2% efficacy with 12-minute median time to conversion
- Key safety observations:
 - Cumulative incidence of HOIs¹ were 0.8%, (95% CI: 0.5%-1.4%)
 - 28 SAEs reported for 26 patients
 - No deaths reported
 - No torsades des pointes



34 ISTs and Other Post-Approval Studies

- Brinavess has been the subject of 34 investigator-sponsored and post-marketing studies which have gathered extensive data in real-world clinical settings



59K

- Over 8 years of real-world experience from over 59,000 patients that have been exposed to Brinavess worldwide

1. HOIs defined as significant hypotension, ventricular arrhythmia, atrial flutter, or bradycardia



Presented
SPECTRUM data
at the upcoming
European Society
of Cardiology 2019
Congress
(Sept 2019; Paris)



Post hoc analysis of
SPECTRUM patients
specifically treated in the
Emergency Room
selected for presentation
at the upcoming American
Heart Association 2019
Annual Meeting
(Nov 16-18; Philadelphia)



Manuscript submitted
to a prestigious U.S.
medical journal for
publication; to coincide
with launch
(first half of 2020)



Planning for a strong
presence at the
upcoming American
College of Cardiology
69th Annual Scientific
Sessions & Expo
(March 2020; Chicago)

New SPECTRUM Data to be Presented at AHA 2019



- New *post hoc* analysis data
- 1,289 unique patients treated specifically in the ER
- 70.2% efficacy with 12-minute median time to conversion
- Median length of hospital stay was 7.5 hours; only 13% of patients were in hospital for >24 hours
- Key safety observations:
 - 12 AEs of special interest in 11 patients¹ (0.9%, [95% CI: 0.4%-1.5%])
 - No SAEs resulted in sequelae, no deaths, and no torsades des pointes

1. The most common of which was significant bradycardia (n=9, 0.6%)

U.S. Market Opportunity – Key Research Findings



Prevalence of Atrial Fibrillation

7.1 million unique patients annually and expected to grow to 9.8M annually by 2030



Cardioversions Performed

According to actual claims data, there are currently >500K cardioversions performed annually in the US



First New Treatment in 10 Years

If approved, Brinavess will address many of the real-world limitations of existing pharmacotherapy for cardioversion and DCCV















\$1B Addressable Market Growing to \$1.9B by 2030

Independent research model projects Brinavess has the potential to generate >\$500M in annual gross sales, based on actual claims data

1. Market research commissioned by Correvio and conducted by a top-tier market research firm. Data collected from actual payors who process 1.3B claims from 1.5M healthcare providers covering 165M persons in the US annually.

4 EU Marketed Products and 2 Major Regulatory Decisions Upcoming

\$21.3M in YTD revenue through September 30, 2019; +8% vs same period in 2018

	Product Brand	Therapeutic Area	Partner / Innovator	Product Positioning
EU		Cardiovascular		<ul style="list-style-type: none"> • 60+ countries • Limited/no promotion (genericized)
		Cardiovascular		<ul style="list-style-type: none"> • Nordics, DE, ES, limited UK (no FR, IT) + Distribution ER setting • More efficient and patient friendly pathway to NSR
		Anti-infective		<ul style="list-style-type: none"> • UK, FR, DE, Nordics plus small EU and Middle East • Hospital avoidance/discharge agent (LA Vanco) • Foundation of anti-infective sales force in those countries
		Anti-infective		<ul style="list-style-type: none"> • All of Europe, except the Nordics • Severely ill HAP patients at risk of complications • Gram+ and some Gram- • Potent against biofilm, rapid, favorable tolerability
		Cardiovascular		<ul style="list-style-type: none"> • All of Europe • Orphan/niche product • Switch from UTHR's Remodulin®
US		Cardiovascular		<ul style="list-style-type: none"> • Q2 2019 resubmission • PDUFA date December 24, 2019

■ Projected Launch



Trevyent
TREPROSTINIL SODIUM

**United
Therapeutics**
C O R P O R A T I O N

- ✓ FDA has accepted United Therapeutics' (NASDAQ: UTHR) Trevyent NDA
- ✓ Assigned a PDUFA date of April 27, 2020
- Correvio plans to submit a regulatory filing for TREVYENT in Europe in second half of 2020


"[Trevyent] is going to be transformative for a very large segment of the pulmonary hypertension population, especially that segment that suffers from connective tissue disease."

"...truly a plug-and-play system."

"[Trevyent]...is going to allow us to significantly expand the reach of subcutaneous Remodulin... well beyond the number of patients that we have already been able to help and serve with that product."

~ Martine Rothblatt, Chairman & CEO, United Therapeutics, on Q3 2019 Earnings Call

Quarterly Sales Evolution



<i>\$ in thousands</i>	Quarter ended	
	September 30, 2019	September 30, 2018
Revenue	\$ 6,669	\$ 7,007
Gross Profit	4,395	4,872
Expenses		
Selling, general and administration	(11,186)	(9,186)
Amortization and depreciation	(984)	(989)
Interest expense	(1,997)	(1,686)
Other expense (FX, Tax, etc.)	(1,006)	(116)
Net loss	(\$10,778)	(\$7,105)
Loss per common share	(\$0.23)	(\$0.20)
Net cash used in operating activities	(\$7,413)	(\$7,460)

Q3 2019 Highlights


- On track to deliver FY 2019 revenues that are 20% above FY 2018
- Cantor equity financing adds gross proceeds of \$13.8M
- First principal debt repayment not due to CRG until June 2020
- Company continues to explore various asset monetization strategies

Cash, cash equivalents, and restricted cash of \$19.7M (as of Sept 30, 2019)




2019

2020



correvio




Question & Answer Session

NASDAQ: CORV / TSX: CORV

correvio

Thank You!



Investor Contacts

Brendan Payne

Assoc. Dir., Investor Relations
and Business Development
Correvio Pharma Corp.
604.677.6905 ext. 306
800.330.9928
bpayne@correvio.com

Argot Partners

Michelle Carroll/Claudia Styslinger
212.600.1902
michelle@argotpartners.com
claudia@argotpartners.com

NASDAQ: CORV / TSX: CORV